About Renerva
Renerva is a company based in Pittsburgh (United States) founded in 2017 by Lorenzo Soletti. Renerva has raised $1.28 million across 8 funding rounds from investors including NIH, HHS and America’s Seed Fund. Renerva offers products and services including Implantable Technologies. Renerva operates in a competitive market with competitors including Avation, Tulavi Nerve Therapeutics, BioCircuit, RxFunction and Epineuron, among others.
- Headquarter Pittsburgh, United States
- Founders Lorenzo Soletti
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Renerva Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.28 M (USD)
in 8 rounds
-
Latest Funding Round
$324.82 K (USD), Seed
Sep 15, 2025
-
Investors
NIH
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Renerva
Renerva offers a comprehensive portfolio of products and services, including Implantable Technologies.
Devices for improving peripheral nerve repair outcomes
People of Renerva
Unlock access to complete
Unlock access to complete
Funding Insights of Renerva
Renerva has successfully raised a total of $1.28M across 8 strategic funding rounds. The most recent funding activity was a Seed round of $324.82 thousand completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Renerva
Renerva has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and America’s Seed Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund backed by the US Government
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked |
Investor details for Renerva
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Renerva
Investment portfolio details for Renerva
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Renerva
Detailed financials for Renerva
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Renerva Comparisons
Peer comparison for Renerva
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Renerva
Renerva operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avation, Tulavi Nerve Therapeutics, BioCircuit, RxFunction and Epineuron, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Wearable tibial nerve stimulation device treats overactive bladder symptoms.
|
|
| Locked | Locked | Locked |
Therapeutic devices for neurally mediated diseases are developed.
|
|
| Locked | Locked | Locked |
Non-invasive electrophysiology devices are developed to monitor peripheral nerves.
|
|
| Locked | Locked | Locked |
Wearable prostheses for sensory peripheral neuropathy patients are developed.
|
|
| Locked | Locked | Locked |
Medical devices for peripheral nerve injury treatment are provided.
|
|
| Locked | Locked | Locked |
Developer of bioimplant for peripheral nerve repair
|
Detailed competitors of Renerva
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Renerva
Complete news archive for Renerva
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Renerva
Renerva was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Renerva is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
Lorenzo Soletti is the current CEO of Renerva. They have also founded this company.
Renerva is a funded company, having raised a total of $1.28M across 8 funding rounds to date.
Renerva was founded in 2017 and is based in Pittsburgh, United States. Focus is placed on the medical device sector, where implants are developed for peripheral nerve repair procedures. These implants address nerve injuries and aim to enhance nerve function. Operations involve research and development in regenerative medicine, with activities centered on therapeutic solutions for peripheral nervous system conditions.
Renerva's top competitors include Avation, Tulavi Nerve Therapeutics and Epineuron.
Renerva offers Implantable Technologies.
Renerva has 4 investors. Key investors include NIH, HHS, America’s Seed Fund, and U.S. Department of Defense.